The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data

Pulmonary Pharmacology and Therapeutics

Volumn 23, Issue 2, 2010, Pages 135-144

  Cazzola, M ^a   Floriani, I ^b   Page, C P ^c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Acute exacerbation; Chronic bronchitis; COPD; Cough; Expectoration; Meta analysis

Indexed keywords

ACETYLCYSTEINE; AMBROXOL; AMINOPHYLLINE; AMOXICILLIN; ANTIBIOTIC AGENT; BACAMPICILLIN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CARBOCISTEINE; COTRIMOXAZOLE; ERDOSTEINE; PLACEBO; SOBREROL; XANTHINE;

AGEUSIA; ALLERGIC REACTION; ARTICLE; ASTHMA; AUSCULTATION; BRONCHITIS; BRONCHOPNEUMONIA; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COUGHING; DATA EXTRACTION; DISEASE EXACERBATION; DRUG CAPSULE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HUMAN; INFORMATION RETRIEVAL; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SPUTUM; SPUTUM VISCOSITY; SYSTEMATIC REVIEW; TREATMENT DURATION;

ADULT; AGED; BRONCHITIS, CHRONIC; COUGH; EXPECTORANTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPUTUM; THIOGLYCOLATES; THIOPHENES; VISCOSITY;

EID: 75749085711     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2009.10.002     Document Type: Article

References (53)

1. Iqbal A., Schloss S., George D., and Isonaka S. Worldwide guidelines for chronic obstructive pulmonary disease: a comparison of diagnosis and treatment recommendations. Respirology 7 (2002) 233-239
2. Miravitlles M., Murio C., Guerriero T., and Gisbert R. Costs of chronic bronchitis and COPD. A one year follow-up study. Chest 123 (2003) 784-791
3. Donaldson G.C., Seemungal T.A.R., Bhowmik A., and Wedzicha J.A. The relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 55 (2002) 847-852
4. Seemungal T.A.R., Donaldson G.C., Paul E.A., Bestall J.C., Jeffries D.J., and Wedzicha J.A. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157 (1998) 1418-1422
5. Miravitlles M., Murio C., Guerriero T., and Gisbert R. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 121 (2002) 1449-1455
6. de Marco R., Accordini S., Cerveri I., Corsico A., Antó J.M., Künzli N., et al. Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. Am J Respir Crit Care Med 175 (2007) 32-39
7. Brusasco V., and Pellegrino R. Airway inflammation in COPD. Friend or foe?. Am J Respir Crit Care Med 176 (2007) 425-429
8. Rabe K.F., Hurd S., Anzueto A., Barnes P.J., Buist S.A., Calverley P., et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176 (2007) 532-555
9. Moretti M. Pharmacology and clinical efficacy of erdosteine in chronic obstructive pulmonary disease. Expert Rev Resp Med 1 (2007) 307-316
10. Moher D., Cook D.J., Eastwood S., Olkin I., Rennie D., and Stroup D.F. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUORUM statement. Lancet 354 (1999) 1896-1900
11. Marchioni C.F., Polu J.M., Taytard A., Hanard T., Noseda G., and Mancini C. Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxicillin as basic treatment (ECOBES, european chronic obstructive bronchitis erdosteine study). Int J Clin Pharmacol Ther 33 (1995) 612-618
12. ® 8erdostéine) versus placebo dans le traitement de la bronchite chronique hypersecrétante stabilisée. Rev Mal Respir 16 (1999) 521-528
13. Arnaud A. Clinical study of efficacy and tolerability of erdosteine in the treatment of chronic obstructive bronchitis with superinfection. Controlled double-blind study vs. N-acetylcysteine. Clinical Study Report EC/ER9022P, Data on File 1991. Partly published in: Mancini C. Erdosteine, the second generation mucolytic: international up-dating of clinical studies (adults and paediatrics).
14. Ricevuti G., Mazzone A., Uccelli E., Gazzani G., and Fregnan G.B. Influence of erdosteine, a mucolytic agent, on amoxicillin penetration into sputum in patients with an infective exacerbation of chornic bronchitis. Thorax 43 (1988) 585-590
15. Hotzinger H. Erdosteine or placebo combined with co-trimoxazole in the treatment of hypersecretive infectious bronchitis: a double blind clinical trial. Med Praxis 12 (1991) 171-181
16. Ginesu F. Controlled clinical trial vs. ambroxol. Clinical Study Report FARMO 83/R, Data on File; 1989.
17. Zanasi A., and Menarini A. Erdosteine versus N-Acetylcysteine in the treatment of exacerbation of chronic bronchopneumopathies: A double blind clinical trial. Med Praxis 12 (1991) 207-217
18. Franco M., and Mancini C. Controlled clinical study of erdosteine in chronic bronchitis patients. Arch Med Interna 47 (1995) 101-111
19. Jadad A.R., Moore A.R., Carroll D., Jenkinson C., Reynolds D.J.M., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 17 (1996) 1-12
20. Higgins J.P.T., Thompson S.G., Deeks J.J., and Altman D.J. Measuring inconsistency in meta-analyses. Br Med J 327 (2003) L 557-L 560
21. Deeks J.J., Altman D.G., and Bradburn M.J. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M., Davey Smith G., and Altman D.G. (Eds). Systematic reviews in health care. Meta-analysis in context. 2nd ed. (2001), BMJ Books, London
22. Marchioni C.F., Moretti M., Muratori M., Casadei M.C., Guerzoni P., Scuri R., et al. Effects of erdosteine on sputum biochemical and rheologic properties: pharmacokinetics in chronic obstructive lung disease. Lung 168 (1990) 285-293
23. Olivieri D., Del Donno M., Casalini A., D'Ippolito R., and Fregnan G.B. Activity of erdosteine on mucociliary transport in patients affected by chronic bronchitis. Respiration 58 (1991) 91-94
24. Grandi M, Zucchi L. A dose effect study of oral erdosteine on rheologic properties of human mucus. Randomised double-blind study with comparison among 3 groups treated with 600 and 900 mg of erdosteine or with placebo. Data on File; 1993.
25. Siquet J. A dose effect study of oral erdosteine on rheological properties of human mucus. Med Praxis 12 (1991) 159-170
26. Nagaoka S. Early phase II trial of KW-9144 on sputum excretion difficulty. Open study with comparison among three doses: 300, 600 and 900 mg/day. Data of File; 1993.
27. Inclimona V. Therapeutic clinical trial with FARMO 83/R: Open design. Data on File; 1985.
28. Cattini G. Efficacy and safety of erdosteine in chronic bronchitis in phase of clinical reactivation: open study. Data on File; 1991.
29. Deodato M. Clinical evaluation of the efficacy and tolerability of erdosteine (450 mg/die per aerosol): open study in the treatment of chronic bronchitis in phase of clinical reactivation. Data on File; 1991.
30. de Castro Pereira C.A., Cardoso A.P., Cavallazzi A.C., Ferreira Pinheiro V.G., de Oliveira M.C., and Esposito C. Efficacy and tolerability of erdosteine in chronic obstructive pulmonary disease. Rev Bras Med 57 (2000) 481-485
31. Rozborilova E., Plutisnký J., and Kogan I. Effect of erdosteine in patients suffering from chronic obstructive pulmonary disease. Slov Lek 9-10 (2002) 308-310
32. Fioretti M., and Bandera M. Prevention of exacerbations in chronic bronchitic patients with erdosteine. Med Praxis 12 (1991) 219-227
33. Ghiringhelli G., and Mancini C. Cross-over clinical study of efficacy and tolerability of erdosteine in the treatment of chronic obstructive bronchial disease in stable hypersecretive phase controlled double-blind study vs placebo. Arch Med Interna 47 (1995) 113-119
34. Moretti M., Bottrighi P., Dallari R., Da Porto R., Dolcetti A., Grandi P., et al. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the equalife study. Drugs Exp Clin Res 30 (2004) 143-152
35. Rossi F. Clinical evaluation of safety and efficacy of erdosteine (450 mg/die per aerosol): double-blind study vs. N-acetylcysteine in the treatment of chronic bronchopneumopathy in phase of clinical reactivation. Data on File; 1991.
36. Kim S.C., Lee S.H., Song S.H., Kim Y.K., Moon H.S., Song J.S., et al. Clinical efficacy of erdosteine in patients with acute or chronic bronchitis: a randomized, double-blind, comparative study vs. ambroxol. Tuberc Respir Dis 44 (1997) 1296-1307
37. Mohanty K.C., Thiappanna G., Singh V., and Mancini C. Evaluation of efficacy and safety of erdosteine in patients affected by exacerbation of chronic bronchitis and receiving ciprofloxacin as basic treatment. J Clin Res 4 (2001) 35-39
38. Tellings J.C. Erdosteine: original secretolytic drug with mucociliar activity. A controlled clinical study versus ambroxol. Med Praxis 12 (1991) 183-195
39. Bisetti A., and Mancini C. Mucolytic activity of erdosteine: double blind clinical trial vs. placebo. Arch Med Interna 47 (1995) 89-97
40. Voisin C. Controlled, double-blind, pilot study comparing erdosteine at the daily dose of 600 mg to placebo in two groups of patients affected by stabilized chronic obstructive bronchitis. Clinical Study Report HEC/ERD/8903P, Data on File; 1990.
41. Stey C., Steurer J., Bachmann S., Medici T.C., and Tramer M.R. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J 16 (2000) 253-262
42. Poole P.J., and Black P.N. Mucolytic agents for chronic bronchitis or chornic obstructive pulmonary disease (Review). Cochrane Database Syst Rev (2006)
43. Marchioni CF. Clinical experience with erdosteine in the treatment of exacerbation of chronic obstructive bronchopneumopathies. Clinical study report FER/05/C300/01, Data on File; 1987.
44. Scarpazza G. Controlled clinical trial of erdosteine in chronic bronchitis under exacerbation. Clinical study report FER/05/C150/01, Data on File; 1987.
45. Fumagalli G., Balzarotti C., Banfi P., Decò P., Ferrante L., and Zennaro M. Erdosteine: a new molecule with mucolytic activity. Clinical and instrumental evaluation in patients with acute exacerbated chronic bronchopneumopathies. It J Chest Dis 42 (1988) 299-308
46. Materazzi F. Evaluation of efficacy and safety of erdosteine in chronic bronchitis in phase of clinical reactivation. Clinical study report EP/S05/C300/0590, Data on File; 1991.
47. Busin S., Clerici R., and Nitti F. Erdosteine: evaluation of mucorheological and immunosecretory parameters in patients with bronchial phlogistic pathology. Med Praxis 12 (1991) 197-205
48. Kharitonov S.A. Fast onset of antioxidant actions of erdosteine and its potential use for acute treatment of COPD exacerbations. Thorax 62 Suppl.III (2007) A47
49. Rossi A., Kristufek P., Levine B.E., Thomson M.H., Till D., Kottakis J., et al. Comparison of the efficacy, tolerability and safety of formoterol dry powder and oral slow-release theophylline in the treatment of COPD. Chest 121 (2002) 1058-1069
50. Szafranski W., Cukier A., Ramirez A., Menga G., Sansores R., Nahabedian S., et al. Efficacy and safety of budesonide/ formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 21 (2003) 74-81
51. Calverley P., Pauwels R., Vesto J., Jones P., Pride N., Gulsvik A., et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361 (2003) 449-456
52. Kline Leidy N., Rennard S.I., Schmier J., Jones M.K.C., and Goldman M. The breathlessness, cough, and sputum scale: the development of empirically based guidelines for interpretation. Chest 124 (2003) 2182-2191
53. Bolser D.C. Cough suppressant and pharmacologic protussive therapy. ACCP evidence-based clinical practice guidelines. Chest 129 (2006) 238S-249S